NGS analyses have shown an absence of mutations in genes typically altered in BL, such as ID3, TCF3, SMARCA4, or CCND3, while mutations in genes typically altered in GCB-DLBCL, such as GNA13 in 50% are the rule, further substantiating the distinctiveness of HGBL-11q from BL and the rationale for changing the name [75,79]. This evidence concerns the gene SMARCA4 and Burkitt lymphoma.